Xenon Pharmaceuticals Inc. (XENE)
D
Pipeline Grade
Financial Position (from SEC Filings)
$545.9M
Cash & Equivalents
$88.9M
Quarterly Burn Rate
18 mo
Est. Cash Runway
$5,026M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase3 Readout | — |
| 2027-01-01 | Phase3 Readout | — |
| 2027-04-01 | Phase3 Readout | — |
| 2027-05-01 | Phase3 Readout | — |
Active Clinical Trials (9)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07076407 | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | PHASE3 | Recruiting | 450 |
| NCT05718817 | An Open-label Study of XEN1101 in Epilepsy | PHASE3 | Enrolling By Invitation | 880 |
| NCT05667142 | A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | PHASE3 | Recruiting | 160 |
| NCT07172516 | A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipola... | PHASE3 | Recruiting | 400 |
| NCT06922110 | An Open-Label Study of Azetukalner in Major Depressive Disorder | PHASE3 | Enrolling By Invitation | 460 |
| NCT07217860 | An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) | PHASE3 | Enrolling By Invitation | 400 |
| NCT06775379 | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | PHASE3 | Recruiting | 450 |
| NCT05716100 | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | PHASE3 | Recruiting | 360 |
| NCT03796962 | A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy | PHASE2 | Active Not Recruiting | 325 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.